Two‐year clinical outcomes of Taiwanese and other Asian ethnicities with atrial fibrillation treated with edoxaban in the ETNA‐AF Asia registry

Abstract Background The non‐vitamin K oral anticoagulant (NOAC), edoxaban, is approved for stroke prevention in patients with atrial fibrillation (AF) in many Asian countries. Nonetheless, data on its long‐term effectiveness and safety in routine clinical practice are limited in Taiwan. Methods The...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Chun‐Chieh Wang MD, Cheng‐I Cheng MD, PhD, Kwo‐Chang Ueng MD, PhD, Wei‐Shiang Lin MD, Tze‐Fan Chao MD, PhD, Lian‐Yu Lin MD, PhD, Chien‐Lung Huang MD, Kuan‐Cheng Chang MD, PhD, Guang‐Yuan Mar MD, Yu‐Cheng Hsieh MD, PhD, Martin Unverdorben MD, PhD, Cathy Chen MD
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Wiley 2025-02-01
Seri Bilgileri:Journal of Arrhythmia
Konular:
atrial fibrillation
edoxaban
long‐term outcome
real‐world evidence
Taiwan
Online Erişim:https://doi.org/10.1002/joa3.13212
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller